Shukra Pharmaceuticals Ltd Stock Price Today (NSE: SHUKRAPHAR)
Fundamental Score
Shukra Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Shukra Pharmaceuticals Ltd share price today is ₹30.34, down 3.42% on NSE/BSE as of 30 March 2026. Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.67K (Cr). The 52-week high for SHUKRAPHAR share price is ₹65.26 and the 52-week low is ₹11.74. At a P/E ratio of 139.49x, SHUKRAPHAR is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.90% and a debt-to-equity ratio of 0.06.
Shukra Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Shukra Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Shukra Pharmaceuticals Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, characterized by stringent regulatory hurdles and extensive research & development, often presents both opportunities and risks for value investors. This analysis focuses on Shukra Pharmaceuticals share price, currently at ₹42.450001, and employs a capital-preservation-first approach. Our preliminary findings, part of a larger 80-parameter fundamental audit verified by Sweta Mishra, seek to assess the company's intrinsic value and financial stability.
One immediate concern arises from the company’s Price-to-Earnings (PE) ratio of 139.49. Compared to the broader market average, this indicates a potentially overvalued stock. A high PE suggests investors are expecting significant future earnings growth, which may or may not materialize. We observe that sector peers like
Mankind Pharma Ltd, known for its seasoned and established management, present a different risk profile. Evaluating the quality and experience of Shukra Pharmaceuticals’ leadership team is crucial to understand the sustainability of their operations and future prospects. Are they capable of navigating regulatory landscapes and driving innovation effectively?Shukra Pharmaceuticals exhibits a Return on Capital Employed (ROCE) of 21.8%. This is a positive sign, suggesting efficient capital allocation and profitability. A consistently high ROCE can contribute to building a competitive moat. Specifically, this level of ROCE could empower the company to reinvest earnings into research, development, or strategic acquisitions, further strengthening its market position and creating barriers to entry for competitors. However, the sustainability of this ROCE needs scrutiny. Is it driven by transient factors or a genuine competitive advantage?
In conclusion, while the 21.8% ROCE indicates potential, the elevated PE ratio necessitates cautious evaluation. The long-term viability of Shukra Pharmaceuticals, particularly its ability to justify the current Shukra Pharmaceuticals share price, depends on its ability to maintain its profitability, navigate industry challenges, and demonstrate superior management compared to its competitors like
Mankind Pharma Ltd. Further investigation into the company's debt levels, cash flow generation, and long-term growth prospects are crucial for making informed decisions with a focus on capital safety.Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Shukra Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SHUKRAPHAR across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (15.90%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (21.15%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (340.74%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (22.45% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (243.88% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (243.61% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (14.50x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (50.96%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 139.49x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Institutional Interest (FII+DII: 0.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Shukra Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Shukra Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About SHUKRAPHAR (Shukra Pharmaceuticals Ltd)
Shukra Pharmaceuticals Ltd is an Indian pharmaceutical company focused on developing, manufacturing, and selling a broad range of medicines both in India and to other countries. Th...ey create and market various types of drugs, including those that fight infections like bacteria and fungi, as well as treatments for malaria, viruses, and parasitic worms. Their product range also extends to medicines for mental health conditions such as depression and anxiety, and treatments for common ailments like ulcers and high blood pressure. The company's main business areas are centered around providing affordable and accessible medicines across diverse therapeutic categories. They make many kinds of products including antibiotics (like penicillin), vitamins, and medications for allergies, diabetes, and tuberculosis. This wide variety helps them reach different segments of the healthcare market and cater to many patient needs. While not one of the very largest pharmaceutical companies, Shukra Pharmaceuticals holds a significant position in the Indian market by supplying essential medicines. Based in Ahmedabad, the company has been operating since 1993 and continues to develop and distribute pharmaceutical products aimed at improving health outcomes. They aim to continue their growth within India's competitive pharmaceuticals sector.
Company Details
Key Leadership
Corporate Events
SHUKRAPHAR Share Price: Frequently Asked Questions
What is the current share price of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
As of 30 Mar 2026, 12:03 pm IST, Shukra Pharmaceuticals Ltd share price is ₹30.34. The SHUKRAPHAR stock has a market capitalisation of ₹1.67K (Cr) on NSE/BSE.
Is SHUKRAPHAR share price Overvalued or Undervalued?
SHUKRAPHAR share price is currently trading at a P/E ratio of 139.49x, compared to the industry average of 31.77x. Based on this relative valuation, the Shukra Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SHUKRAPHAR share price?
The 52-week high of SHUKRAPHAR share price is ₹65.26 and the 52-week low is ₹11.74. These values are updated daily from NSE/BSE price data.
What factors affect the Shukra Pharmaceuticals Ltd share price?
Key factors influencing SHUKRAPHAR share price include quarterly earnings growth (Sales Growth: 5.76%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Shukra Pharmaceuticals Ltd a good stock for long-term investment?
Shukra Pharmaceuticals Ltd shows a 5-year Profit Growth of 243.61% and an ROE of 15.90%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.06 before investing in SHUKRAPHAR shares.
How does Shukra Pharmaceuticals Ltd compare with its industry peers?
Shukra Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare SHUKRAPHAR share price P/E of 139.49x and ROE of 15.90% against the industry averages to determine competitive standing.
What is the P/E ratio of SHUKRAPHAR and what does it mean?
SHUKRAPHAR share price has a P/E ratio of 139.49x compared to the industry average of 31.77x. Investors pay ₹139 for every ₹1 of annual earnings.
How is SHUKRAPHAR performing according to Bull Run's analysis?
SHUKRAPHAR has a Bull Run fundamental score of 62.1/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SHUKRAPHAR belong to?
SHUKRAPHAR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Shukra Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for SHUKRAPHAR?
SHUKRAPHAR has an ROE of 15.90%, which indicates excellent management efficiency. ROE measures how efficiently Shukra Pharmaceuticals Ltd generates profits from shareholders capital.
How is SHUKRAPHAR debt-to-equity ratio and what does it indicate?
SHUKRAPHAR has a debt-to-equity ratio of 0.06, which indicates conservative financing with low financial risk.
What is SHUKRAPHAR dividend yield and is it a good dividend stock?
SHUKRAPHAR offers a dividend yield of 0.03%, meaning you receive ₹0.03 annual dividend for every ₹100 invested in Shukra Pharmaceuticals Ltd shares.
How has SHUKRAPHAR share price grown over the past 5 years?
SHUKRAPHAR has achieved 5-year growth rates of: Sales Growth 22.45%, Profit Growth 243.61%, and EPS Growth 243.88%.
What is the promoter holding in SHUKRAPHAR and why does it matter?
Promoters hold 50.96% of SHUKRAPHAR shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Shukra Pharmaceuticals Ltd.
What is SHUKRAPHAR market capitalisation category?
SHUKRAPHAR has a market capitalisation of ₹1668 crores, placing it in the Small-cap category.
How volatile is SHUKRAPHAR stock?
SHUKRAPHAR has a beta of N/A. A beta > 1 suggests the Shukra Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SHUKRAPHAR operating profit margin trend?
SHUKRAPHAR has a 5-year average Operating Profit Margin (OPM) of 21.15%, indicating the company's operational efficiency.
How is SHUKRAPHAR quarterly performance?
Recent quarterly performance shows Shukra Pharmaceuticals Ltd YoY Sales Growth of 5.76% and YoY Profit Growth of 340.74%.
What is the institutional holding pattern in SHUKRAPHAR?
SHUKRAPHAR has FII holding of 0.00% and DII holding of 0.11%. Significant institutional holding often suggests professional confidence in the Shukra Pharmaceuticals Ltd stock.